C&L: Waddick takes reins at Vasogen

Chris Waddick, MBA, CMA, has been appointed president and CEO of Vasogen, succeeding Terrance Gregg, who will remain as chairman of the board of directors.

Bruce Given left his post as CEO of Encysive as the company announced deep cuts in its workforce.

NexMed has named Vivian Liu as chief executive, replacing Richard J. Berman, who was elected non-executive chairman.

Genocea Biosciences has hired George R. Siber, M.D. as executive chairman.

Norris Tolson was selected president and CEO of the North Carolina Biotechnology Center.

Lisa Evren has joined Merrimack as senior vice president and CFO.

Presidio Pharmaceuticals has hired Marcus Conant, MD as its chief medical officer and Antoun Nabhan, JD as CFO.

Steve Glover has joined Insmed's management team as president of the newly formed Follow-on Biologics business.

Transave has appointed Nicholas Gurreri as senior vice president, commercial operations and business development.

Acusphere says that CFO John F. Thero, who also held the senior vice president, finance and administration, treasurer and secretary titles, will step down to pursue other interests. Frederick Ahlholm, Acusphere's vice president of finance, will be interim principal financial officer.

MDS Pharma has named Howard Moody to the position of vice-president of information technology.

Taconic has hired Scott Schulz as vice president of operations.

Novagali Pharma has named Sylvie Elia-Foeillet vice president of pharmaceutical affairs and Genevieve Garrigos as vice president of human resources and communication.

Andy H. Strayer, Pharm.D., has joined Naryx Pharma as vice president of clinical operations and medical affairs.

NanoMed Pharmaceuticals has hired Harry C. Ledebur, Jr., PhD. to serve as the company's vice president research & development, chief scientific officer.

PTC Therapeutics has named Manal Morsy, M.D., Ph.D. as vice president of regulatory affairs.

Plexxikon announced that Gary C. Visor, Ph.D. was named vice president, pharmaceutics, a new position responsible for managing pharmaceutical drug substance scale-up, manufacturing and dosage design and development, required for the company's development programs. In addition, David H. MacCallum has been appointed to Plexxikon's board of directors.

Matthew S. Zelinski has joined Monogen as vice president, research and development.

Dmitry Samarsky, Ph.D., has joined RXi as vice president of technology development.

Elusys Therapeutics has named Jeremy D. Middleton as vice president of corporate development.

Phytopharm has announced the appointment of Alistair Taylor as nonexecutive chairman.

Patheon Inc. announced today that George L. Ploder has resigned as a director.

Adenosine Therapeutics announced the appointment of Dr. Jonathan Sackier and Dr. Steven Tregay to its board of directors.

Genesis Bioventures has accepted the resignation of Antony S. Dyakowski, one of its former directors.

Auriga Laboratories has appointed Leonhard Dreimann and Thomas Heck to its board of directors.

Kathleen M. Wiltsey has been elected to Sequenom's board of directors

Robert J. Levenson he been elected to the board of directors at Elite Pharmaceuticals.

The Burnham Institute has elected six new board members: Brigitte M. Bren; Robert J. Lauer; Robert A. Mandell; Jan Tuttleman; Andrew J. Viterbi; and Gayle E. Wilson.

Metabolex has elected Robert B. Chess to its board of directors.

MAP Pharmaceuticals has named Bernard J. Kelley to the company's board of directors.

EyeGate Pharma has appointed Richard Guy, Ph.D., to its Scientific Advisory Board.

TheraQuest Biosciences announced the appointment of Drs. Cynthia McCormick and Nathaniel Katz to its Scientific Advisory Board.

LifeCycle Pharma has established a Scientific Advisory Board for its transplantation programs.